La genetica del carcinoma colo-rettale
|
|
- Noel Adams
- 6 years ago
- Views:
Transcription
1 La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona
2 OUTLINE What s new in colorectal cancer? Pathological Markers Molecular Markers Future perspectives: between hope and reality
3 OUTLINE What s new in colorectal cancer? Pathological Markers Molecular Markers Future perspectives: between hope and reality
4 CRC: Pathological Markers
5 CRC: Histology Report 1994 ANATOMIA PATOLOGICA ROSSI MARIO HISTOLOGY Histotype grading metastases Surgical margins 2016 REGIONE VENETO UNITÀ OPERATIVA DI ANATOMIA PATOLOGICA ROSSI MARIO HISTOLOGY Histotype Grading Metastases Surgical margins/mesorectum Budding Vascular/perineural invasion Tumor Regression Grade ptnm IHC/ISH MMR genes/cdx2/her2 Isolated tumor cells (ITC) MOLECULAR TESTS KRAS, BRAF, NRAS Microsatellite instability
6 CRC: Molecular Markers microsatellite instability (MSI) CpG island methylator phenotype (CIMP) somatic mutations in KRAS somatic mutations in BRAF
7 CRC: Molecular Markers Integrated histological and molecular classification microsatellite instability (MSI) somatic mutations in KRAS CpG island methylator phenotype (CIMP) somatic mutations in BRAF Adenoma-carcinoma pathway (conventional) MSS BRAF & KRAS wt Serrated pathway CIMP-L/CIMP-H BRAF mut Alternative pathway MSS CIMP-L & KRAS mut
8 Conventional pathways APC Normal mucosa APC Hypometilation, SMAD4, TP53 Tubular adenoma Tubulovillous adenoma KRAS TP53 CIMP- MSS Sensitive 5FU Sensitive aegfr KRAS, CIMP-L MSS Sensitive 5FU Resistant aegfr Bettington M, et al. Histopathology 2013
9 Serrated pathways BRAF, CIMP-H Normal mucosa KRAS MLH1, MSI, IGFR2, TGFRβ Sessile serrated adenoma CDKN2A, MGMT Traditional serrated adenoma Tubulovillous adenoma with serrated features Wnt pathway BRAF, CIMP-H MSI Resistant 5FU Resistant aegfr BRAF, CIMP-H MSS Sensitive 5FU Resistant aegfr KRAS, CIMP-L MSS Sensitive 5FU Resistant aegfr Bettington M, et al. Histopathology 2013
10 MSI related CRCs 15% CRC have defective DNA mismatch repair (dmmr) 70% sporadic MLH1 methylation 30% hereditary Mutations in MMR genes Diagnosis testing for loss of the protein products for genes involved in DNA mismatch repair, most commonly MLH1, MSH2, MSH6, and PMS2 presence of microsatellite instability (MSI) proximal mucinous diploid
11 Defective Mismatch Repair: a predictive marker for lack of efficacy of Fluorouracil-based adjuvant therapy untreated Stage III dmmr Stage III pmmr High-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dmmr) have improved survival and receive no benefit from fluorouracil (FU)-based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pmmr) tumors. Sargent DJ, et al. JCO 2010
12 CIMP is associated with response to adjuvant Irinotecan-based therapy for stage III CRC - CIMP (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) is frequently associated to dmmr due to inactivation of MLH1. - CIMP is observed in 15-20% CRC. proximal women BRAF G3 Shiovitz S, et al. Gastroenterology 2014
13 CIMP is associated with response to adjuvant Irinotecan-based therapy for stage III CRC - CIMP (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) is frequently associated to dmmr due to inactivation of MLH1. - CIMP is observed in 15-20% CRC. proximal women BRAF G3 HR=1,36 CIMP neg 615 CRCs 23% CIMP+* 77% CIMP-neg CIMP + CIMP-positive tumors had shorter overall survival (FU/LV) (hazard ratio [HR]=1.36) * 4 met in at least 3 of 5 CpG island Shiovitz S, et al. Gastroenterology 2014
14 CIMP is associated with response to adjuvant Irinotecan-based therapy for stage III CRC - CIMP (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) is frequently associated to dmmr due to inactivation of MLH1. - CIMP is observed in 15-20% CRC. proximal women BRAF G3 HR=1,36 CIMP +/IFL CIMP +/FL CIMP+ tumors benefit most from the addition of irinotecan to fluorouracil/leucovorin therapy (for the interaction, P = 0.01). IFL: Irinotecan+Fluoruracil+Leucovorin FL: Fluoruracil+Leucovorin Shiovitz S, et al. Gastroenterology 2014
15 CIMP is associated with response to adjuvant Irinotecan-based therapy for stage III CRC - CIMP (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) is frequently associated to dmmr due to inactivation of MLH1. - CIMP is observed in 15-20% CRC. proximal women BRAF G3 60% 35% CIMP+/MMR-i Irin+FU-LV CIMP+/MMR-i FU-LV Stage III, CIMP+, MMR-i colon tumors have longer overall survival when irinotecan is added to combination therapy with fluorouracil and leucovorin. Shiovitz S, et al. Gastroenterology 2014
16 Classification of CRC based on correlation of clinical, morphological and molecular features Type microsatellite H - or L - or L - or L H CIMP + + L - - KRAS BRAF Jass JR, et al. Histopathology 2007
17 Association between molecular subtypes of colorectal cancer and patient survival *Stage adjusted Disease Specific Survival* other n= 2, years type 4 is the most predominant (47%) (APC-conventional pat.) type 2 had the highest disease-specific mortality (HR=2.20, 95% CI: ) (MSS-CIMP-BRAF sessile-serrated pat.) type 1 and type 5 have the lowest disease-specific mortality (HR=0.30, 95% CI: ) (MSI-related pat.) the clinical importance of studies into the molecular heterogeneity of CRC!! Phipps AI, et al. Gastroenterology 2014
18 The CRC Subtyping Consortium Analysis of 6 independent gene-expression based classification systems Identification of 4 robust CMSs [ ] none of the subtypes is defined by an individual event, nor is any genetic aberration limited to a subtype. Guinney J,et al, Nature Medicine (12 October 2015)
19 Integrated histological and molecular classification Consensus Molecular Subtypes * * * Female, right colon, high grade, Superior survival after relapse Left side More advanced stage *SCNA: somatic copy number alterations Guinney J,et al, Nature Medicine (12 October 2015)
20 OUTLINE What s new in colorectal cancer? - Clinical and pathological factors - Molecular markers Future perspectives: between hope and reality
21 The future in molecular oncology: clinical genomics? Highly selective testing Stepwise, single-gene testing algorithms tailored to specific cancers KRAS mutation Multiplex testing Simultaneous multigene and multiplexed approach DNA RNA Unbiased testing Global and unbiased whole-genome approach DNA RNA NRAS mutation Multiplexed mutation testing Multiplexed RNA profiling and fusion transcript detection Whole-exome (or genome) sequencing Whole-transcriptome sequencing (including paired ends) BRAF mutation Genomic copy number profiling Present Future Taylor BS & Ladanyi M J Pathol 2011
22 The future in molecular oncology: clinical genomics? Highly selective testing Stepwise, single-gene testing algorithms tailored to specific cancers KRAS mutation Multiplex testing Simultaneous multigene and multiplexed approach DNA RNA Unbiased testing Global and unbiased whole-genome approach DNA RNA NRAS mutation Multiplexed mutation testing Multiplexed RNA profiling and fusion transcript detection Whole-exome (or genome) sequencing Whole-transcriptome sequencing (including paired ends) BRAF mutation Genomic copy number profiling Future Present Taylor BS & Ladanyi M J Pathol 2011
23 FFPE tissue 10/40 ng DNA genes >2,000 hotspots mutations >200 PCR in one tube
24 The liquid biopsy era: a short life for pathologists? Crowley E, et al. - Nat Rev Clin Oncol 2013
25 The liquid biopsy as a mini-invasive CRC diagnostic tool 100% 50% 0% Localized Metastatic ctdna was detected in 73% of patients with early CRC ctdna was often present without detectable circulating tumor cells Bettegowda C, et al Sci Transl Med 2014
26 The liquid biopsy as a miniinvasive CRC diagnostic tool n=206 KRAS exon WT 78 mut 127 WT 1 mut 68 mut 10 WT Specificity 99.2% Sensitivity 87.2% The concordance of KRAS mut status among tissue samples and plasma was 95% (k=0,88 P>0,0001) Bettegow DA, et al Sci Transl Med 2014
27 The liquid biopsy : monitoring patients for resistance-conferring mutations n= 24 KRAS, NRAS, BRAF, PIK3CA & EGFR wt 23/24 (96%) presented emergent circulating mutations of at least one mitogen-activated protein kinase pathway gene during treatment More than one mutation per gene!!! METASTASES HETEROGENEITY Bettegowda C, et al Sci Transl Med 2014
28 micrornas: the new actors in the cancer scenario Biomarkers Diagnosis Prognosis Therapeutics Fassan M & Baffa R Curr Opin Genet Dev 2013
29 micrornas: the new actors in the cancer scenario one-third of protein-coding human mrnas are susceptible to this complex mirna regulatory network Normal Cancer mir-21 PDCD4 mirna t.s.gene mirna as oncogene let-7 RAS; C-MYC mirna oncogene mirna as tumor suppressor gene Fassan M, Croce CM & Rugge M World J Gastroenterol 2011
30 Circulating mir-182 is a biomarker of colorectal adenocarcinoma progression Plasma!! N vs K I-II vs III-IV pre vs post Perilli L, et al Oncotarget 2014
31 Richiesta esame istologico REGIONE VENETO CLINICA CHIRURGICA 78 Direttore Prof Rossi Maria Data nascita 01/08/1956 Codice fiscale RSSMRO89H872B ROSSI MARIO Codice a barre Comune di residenza Peschiera del Garda MATERIALE INVIATO Liver biopsy V segment NOTIZIE CLINICHE RICHIESTA Mutational profiling Dott. Giacomo
32 Richiesta esame istologico REGIONE VENETO CLINICA CHIRURGICA 78 Direttore Prof Rossi Maria Data nascita 01/08/1956 Codice fiscale RSSMRO89H872B ROSSI MARIO Codice a barre Comune di residenza Peschiera del Garda MATERIALE INVIATO Liver biopsy V segment NOTIZIE CLINICHE CRC Liver metastasis RICHIESTA Histology, EGFR IHC, EGFR FISH, KRAS, BRAF, NRAS, PI3K, TP53, DPC4, ZEB2, CIP&CIOP Dott. Giacomo
33 Richiesta esame istologico REGIONE VENETO CLINICA CHIRURGICA 78 Normal parenchyma Data nascita 01/08/1956 Codice fiscale RSSMRO89H872B Direttore Prof Rossi Maria ROSSI MARIO Codice a barre MATERIALE INVIATO Liver biopsy V segment Comune di residenza Peschiera del Garda Necrosis Fibrosis NOTIZIE CLINICHE CRC Liver metastasis % tumor cells RICHIESTA Histology, EGFR IHC, EGFR FISH, KRAS, BRAF, NRAS, PI3K, TP53, DPC4, ZEB2, CIP&CIOP Mutational Profiling is not the diagnosis! Dott. Giacomo
34 Richiesta esame istologico REGIONE VENETO Data nascita 01/08/1956 Codice fiscale RSSMRO89H872B CLINICA CHIRURGICA 78 Direttore Prof Rossi Maria ROSSI MARIO Codice a barre MATERIALE INVIATO Liver biopsy V segment Comune di residenza Peschiera del Garda the sharing of the procedures among the multidisciplinary team NOTIZIE CLINICHE CRC Liver metastasis RICHIESTA Histology, EGFR IHC, EGFR FISH, KRAS, BRAF, NRAS, PI3K, TP53, DPC4, ZEB2, CIP&CIOP Dott. Giacomo
35 Conclusions The histology report represent a crucial point for CRC management Not so far from a definitive CRC histo-molecular classification Next-generation diagnostics in old-generation laboratories Sharing of ideas among the multidisciplinary team Liquid biopsy: they still need us!
36 Grazie
Serrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationHisto-prognostic factors what histopathology has to offer for clinical decision making
Histo-prognostic factors what histopathology has to offer for clinical decision making Daniela E. Aust Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationBiology of cancer development in the GI tract
1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationColon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP
Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationEarly (and not so early) colorectal cancer: The pathologist s point of view
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationMolecular Aspects of Colorectal Cancer for the Practicing Surgical Pathologist
Molecular Aspects of Colorectal Cancer for the Practicing Surgical Pathologist Murray Resnick MD PhD Vice Chief of Pathology, Director Anatomical Pathology Rhode Island and The Miriam Hospital Professor
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationDisclosure slide I Member of advisory board for AMGEN, ROCHE, BOEHRINGER I Speaker honoraria from FALK Pharma, Pfizer, Lilly and ROCHE I Third party f
Early (and not so early) colorectal cancer: The pathologist s point of view Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory board for
More informationSupplementary Table 1. PIK3CA mutation in colorectal cancer
Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 1 Supplementary Table 1. PIK3CA mutation in colorectal cancer Exon Domain Nucleotide change* Amino acid change* cases 9 Helical c.1621t>a p.e541t
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationMicrosatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France
Microsatellite instability and other molecular markers: how usefulare they? Pr Frédéric Bibeau, MD, PhD Pathology Department CHU de Caen France Content - Colorectal cancer context - CRC molecular classification
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationClinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer Shuji Ogino, M.D., Ph.D. Associate Professor of Pathology Harvard Medical School Brigham and Women s Hospital Dana-Farber
More informationColorectal cancer molecular biology moves into clinical practice
1 Department of Laboratory Medicine, University of Washington, Washington, USA 2 Clinical Research Division, Fred Hutchison Cancer Research Center, Washington, USA 3 Department of Medicine, University
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationThe silence of the genes: clinical applications of (colorectal) cancer epigenetics
The silence of the genes: clinical applications of (colorectal) cancer epigenetics Manon van Engeland, PhD Dept. of Pathology GROW - School for Oncology & Developmental Biology Maastricht University Medical
More informationDisclosures 9/25/2012. Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC)
Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC) Disclosures 21 st ANNUAL SYMPOSIUM ON MOLECULAR PATHOLOGY Clinical Applications
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationColorectal cancer: pathology
UK NEQAS for Molecular Pathology Colorectal cancer: pathology Nick West Pathology & Tumour Biology May 2013 Colorectal cancer (CRC) 40,695 new cases in 2010 15,708 deaths Management of CRC Surgery Main
More informationMolecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma
Molecular Biomarkers in the Characterization & Treatment of Colorectal Carcinoma Andrew C. Nelson, M.D., Ph.D. Divisions of Anatomic & Molecular Pathology Department of Laboratory Medicine & Pathology
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationWat is de potentiële waarde van ctdna? PLCRC - MEDOCC
Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationNew molecular targets in lung cancer therapy
New molecular targets in lung cancer therapy Giuseppe Pelosi Pathology Division, Science & Technology Park, IRCCS Multimedica, Milan Milan - Italy Advanced lung cancer (IIIB IV) Subtyping Oncogene addiction
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationSerrated Colorectal Polyps and the Serrated Neoplasia Pathway
Serrated Colorectal Polyps and the Serrated Neoplasia Pathway An update on the pathology and clinical significance Mark Be(ngton Envoi Specialist Pathologists Overview 1. A framework of what is included
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationBiomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin)
Recent advances in the management of CRC II 2017/12/17 (Sun.) 10:10-11:00 Biomarkers to optimize treatment selection in colorectal cancer Edwin Pun HUI, MBChB, MD, FRCP (Lond & Edin) Department of Clinical
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationPathology of serrated colorectal lesions
Correspondence to Dr Adrian C Bateman, Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, MP002, Level E, South Block, Southampton General Hospital, Tremona Road, Southampton
More informationArzu Ensari, MD, PhD Department of Pathology Ankara University Medical School
Precursors of Colorectal Carcinoma Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School Hyperplastic polyp Adenomatous polyp Colorectal carcinoma IBD-associated (1-2%) Sporadic
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationNature Medicine: doi: /nm.3967
Supplementary Figure 1. Network clustering. (a) Clustering performance as a function of inflation factor. The grey curve shows the median weighted Silhouette widths for varying inflation factors (f [1.6,
More informationGastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular Knowledge on Carcinogenesis
Human Journals Research Article March 2018 Vol.:11, Issue:4 All rights are reserved by Stefania Erra et al. Gastric Adenocarcinoma: Study of the Immunophenotypic Profile in View of the Latest Molecular
More informationEarly colorectal cancer Quality and rules for a good pathology report Histoprognostic factors
Early colorectal cancer Quality and rules for a good pathology report Histoprognostic factors Frédéric Bibeau, MD, PhD Pathology department Biopathology unit Institut du Cancer de Montpellier France Quality
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationLYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!
LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationOncologist. The. Academia Pharma Intersect: Gastrointestinal Cancer
The Oncologist Academia Pharma Intersect: Gastrointestinal Cancer Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationIntroduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory
Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More information